Ardelyx (ARDX) has quietly established itself as one of the most fascinating biotech stories, trading at under $10. With two FDA-approved therapies on the market, IBSRELA and XPHOZAH, delivering consistent growth, Ardelyx is not just another speculative clinical-stage biotech. It is building a sustainable commercial business in specialty medicine. The company’s second-quarter results showed a kind of momentum rarely seen in small-cap biotech. More News from Barchart Valued at$1.5 billion, ARDX stock ha ...